Mark F. Lunt

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 199 publications

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 03, 2026

Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study.

Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 03, 2026

Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Journal: The British journal of dermatology

Published: February 24, 2026

Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasis.

Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasis.

Journal: The British journal of dermatology

Published: February 16, 2026

Serious infections in children and young people with psoriasis on systemic treatments.

Serious infections in children and young people with psoriasis on systemic treatments.

Journal: The British journal of dermatology

Published: February 11, 2026

Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Journal: The British journal of dermatology

Published: January 28, 2026

Serious infection risk in people treated with infliximab for severe psoriasis.

Serious infection risk in people treated with infliximab for severe psoriasis.

Journal: The British journal of dermatology

Published: November 18, 2025

Opioid-specific risk of respiratory depression in non-cancer pain: a retrospective cohort study.

Opioid-specific risk of respiratory depression in non-cancer pain: a retrospective cohort study.

Journal: BMC medicine

Published: October 27, 2025

Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence.

Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence.

Journal: Dermatology and therapy

Published: August 11, 2025

Comparative risk of delirium among opioid users for non-cancer pain: a retrospective cohort study.

Comparative risk of delirium among opioid users for non-cancer pain: a retrospective cohort study.

Journal: BMC medicine

Published: June 25, 2025

Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis.

Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis.

Journal: JAMA dermatology

Published: March 05, 2025

Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort.

Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort.

Journal: Clinical and experimental dermatology

Published: February 08, 2025

Showing 1-12 of 199

Last Updated: 09/26/2026